Pliant Therapeutics/PLRX

$14.15

-2.21%
-
1D1W1MYTD1YMAX

About Pliant Therapeutics

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Ticker

PLRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bernard Coulie

Employees

158

Headquarters

South san francisco, United States

PLRX Metrics

BasicAdvanced
$852.38M
Market cap
-
P/E ratio
-$2.75
EPS
1.13
Beta
-
Dividend rate
$852.38M
1.13212
$30.85
$12.61
380.4K
17.722
2.123
2.123
-37.4%
-41%
-39.82%
539.484
1.79
1.8
-83.69%
7.4%
-66.44%

What the Analysts think about PLRX

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 13 analysts.
193.57% upside
High $54.00
Low $24.00
$14.15
Current price
$41.54
Average price target

PLRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-41.1M
-0.72%
Profit margin
0%
-

PLRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.22%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.67
-$0.70
-$0.70
-$0.69
-
Expected
-$0.67
-$0.71
-$0.78
-$0.81
-$0.77
Surprise
0.25%
-1.87%
-9.68%
-15.22%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Pliant Therapeutics stock?

Pliant Therapeutics (PLRX) has a market cap of $852.38M as of April 15, 2024.

What is the P/E ratio for Pliant Therapeutics stock?

The price to earnings (P/E) ratio for Pliant Therapeutics (PLRX) stock is 0 as of April 15, 2024.

Does Pliant Therapeutics stock pay dividends?

No, Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Pliant Therapeutics dividend payment date?

Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Pliant Therapeutics?

Pliant Therapeutics (PLRX) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Pliant Therapeutics stock price target?

The target price for Pliant Therapeutics (PLRX) stock is $41.54, which is 193.57% above the current price of $14.15. This is an average based on projections from 13 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pliant Therapeutics stock

Buy or sell Pliant Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing